Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew L. Snow is active.

Publication


Featured researches published by Andrew L. Snow.


Cell | 2007

Ribosomal Protein S3: A KH Domain Subunit in NF-κB Complexes that Mediates Selective Gene Regulation

Fengyi Wan; D. Eric Anderson; Robert A. Barnitz; Andrew L. Snow; Nicolas Bidère; Lixin Zheng; Vijay Hegde; Lloyd T. Lam; Louis M. Staudt; David Levens; Walter A. Deutsch; Michael J. Lenardo

NF-kappaB is a DNA-binding protein complex that transduces a variety of activating signals from the cytoplasm to specific sets of target genes. To understand the preferential recruitment of NF-kappaB to specific gene regulatory sites, we used NF-kappaB p65 in a tandem affinity purification and mass spectrometry proteomic screen. We identified ribosomal protein S3 (RPS3), a KH domain protein, as a non-Rel subunit of p65 homodimer and p65-p50 heterodimer DNA-binding complexes that synergistically enhances DNA binding. RPS3 knockdown impaired NF-kappaB-mediated transcription of selected p65 target genes but not nuclear shuttling or global protein translation. Rather, lymphocyte-activating stimuli caused nuclear translocation of RPS3, parallel to p65, to form part of NF-kappaB bound to specific regulatory sites in chromatin. Thus, RPS3 is an essential but previously unknown subunit of NF-kappaB involved in the regulation of key genes in rapid cellular activation responses. Our observations provide insight into how NF-kappaB selectively controls gene expression.


Journal of Clinical Investigation | 2009

Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency

Andrew L. Snow; Rebecca A. Marsh; Scott M. Krummey; Philip Roehrs; Lisa R. Young; Kejian Zhang; Jack van Hoff; Deepali Dhar; Kim E. Nichols; Alexandra H. Filipovich; Helen C. Su; Jack Bleesing; Michael J. Lenardo

X-linked lymphoproliferative disease (XLP) is a rare congenital immunodeficiency that leads to an extreme, usually fatal increase in the number of lymphocytes upon infection with EBV. It is most commonly defined molecularly by loss of expression of SLAM-associated protein (SAP). Despite this, there is little understanding of how SAP deficiency causes lymphocytosis following EBV infection. Here we show that T cells from individuals with XLP are specifically resistant to apoptosis mediated by TCR restimulation, a process that normally constrains T cell expansion during immune responses. Expression of SAP and the SLAM family receptor NK, T, and B cell antigen (NTB-A) were required for TCR-induced upregulation of key pro-apoptotic molecules and subsequent apoptosis. Further, SAP/NTB-A signaling augmented the strength of the proximal TCR signal to achieve the threshold required for restimulation-induced cell death (RICD). Strikingly, TCR ligation in activated T cells triggered increased recruitment of SAP to NTB-A, dissociation of the phosphatase SHP-1, and colocalization of NTB-A with CD3 aggregates. In contrast, NTB-A and SHP-1 contributed to RICD resistance in XLP T cells. Our results reveal what we believe to be novel roles for NTB-A and SAP in regulating T cell homeostasis through apoptosis and provide mechanistic insight into the pathogenesis of lymphoproliferative disease in XLP.


Immunity | 1998

FRIP, a Hematopoietic Cell-Specific rasGAP-Interacting Protein Phosphorylated in Response to Cytokine Stimulation

Keats Nelms; Andrew L. Snow; Jane Hu-Li; William E. Paul

The human IL-4 receptor contains a sequence (the 14R motif) centered on Y497 that, when phosphorylated, interacts with phosphotyrosine-binding (PTB) domain proteins. Here, we describe a PTB domain protein, FRIP, that is phosphorylated in response to cytokine stimulation. FRIP is related to the rasGAP-associated protein p62dok and is bound by the N-terminal SH2 domain of rasGAP. The frip gene maps to the hairless (hr) locus on mouse chromosome 14. hr/hr mice exhibit lymphadenopathy, and their lymph node T cells proliferate more vigorously to anti-CD3 with IL-4 or IL-2 stimulation than +/hr T cells. FRIP expression is significantly reduced in T cells from hr/hr mice. FRIP may negatively regulate proliferation by acting as an adapter molecule between rasGAP and receptor complexes.


Blood | 2010

X-linked lymphoproliferative syndromes: brothers or distant cousins?

Alexandra H. Filipovich; Kejian Zhang; Andrew L. Snow; Rebecca A. Marsh

X-linked lymphoproliferative disease (XLP1), described in the mid-1970s and molecularly defined in 1998, and XLP2, reported in 2006, are prematurely lethal genetic immunodeficiencies that share susceptibility to overwhelming inflammatory responses to certain infectious triggers. Signaling lymphocytic activation molecule-associated protein (SAP; encoded by SH2D1A) is mutated in XLP1, and X-linked inhibitor of apoptosis (XIAP; encoded by BIRC4) is mutated in XLP2. XLP1 is a disease with multiple and variable clinical consequences, including fatal hemophagocytic lymphohistiocytosis (HLH) triggered predominantly by Epstein-Barr virus, lymphomas, antibody deficiency, and rarer consequences of immune dysregulation. To date, XLP2 has been found to cause HLH with and without exposure to Epstein-Barr virus, and HLH is commonly recurrent in these patients. For both forms of XLP, the only curative therapy at present is allogeneic hematopoietic cell transplantation. Beyond their common X-linked locus and their requirement for normal immune responses to certain viral infections, SAP and XIAP demonstrate no obvious structural or functional similarity, are not coordinately regulated with respect to their expression, and do not appear to directly interact. In this review, we describe the genetic, clinical, and immunopathologic features of these 2 disorders and discuss current diagnostic and therapeutic strategies.


Journal of Experimental Medicine | 2012

Congenital B cell lymphocytosis explained by novel germline CARD11 mutations

Andrew L. Snow; Wenming Xiao; Jeffrey R. Stinson; Wei Lu; Benjamin Chaigne-Delalande; Lixin Zheng; Stefania Pittaluga; Helen F. Matthews; Roland Schmitz; Sameer Jhavar; Stefan Kuchen; Lela Kardava; Wei Wang; Ian T. Lamborn; Huie Jing; Mark Raffeld; Susan Moir; Thomas A. Fleisher; Louis M. Staudt; Helen C. Su; Michael J. Lenardo

Germline mutations in CARD11 that result in constitutive NF-κB activation and selective B cell expansion underlie congenital B cell lymphocytosis.


Current Biology | 2006

Caspase-8 Regulation by Direct Interaction with TRAF6 in T Cell Receptor-Induced NF-κB Activation

Nicolas Bidère; Andrew L. Snow; Keiko Sakai; Lixin Zheng; Michael J. Lenardo

Triggering of lymphocyte antigen receptors is the critical first step in the adaptive immune response against pathogens. T cell receptor (TCR) ligation assembles a large membrane signalosome, culminating in NF-kappaB activation [1,2]. Recently, caspase-8 was found to play a surprisingly prominent role in lymphocyte activation in addition to its well-known role in apoptosis [3]. Caspase-8 is activated after TCR stimulation and nucleates a complex with B cell lymphoma 10 (BCL10), paracaspase MALT1, and the inhibitors of kappaB kinase (IKK) complex [4]. We now report that the ubiquitin ligase TRAF6 binds to active caspase-8 upon TCR stimulation and facilitates its movement into lipid rafts. We identified in silico two putative TRAF6 binding motifs in the caspase-8 sequence and found that mutation of critical residues within these sites abolished TRAF6 binding and diminished TCR-induced NF-kappaB activation. Moreover, RNAi-mediated silencing of TRAF6 abrogated caspase-8 recruitment to the lipid rafts. Protein kinase Ctheta (PKCtheta), CARMA1, and BCL10 are also required for TCR-induced caspase-8 relocation, but only PKCtheta and BCL10 control caspase-8 activation. Our results suggest that PKCtheta independently controls CARMA1 phosphorylation and BCL10-dependent caspase-8 activation and unveil an essential role for TRAF6 as a critical adaptor linking these two convergent signaling events.


Immunological Reviews | 2010

The power and the promise of restimulation-induced cell death in human immune diseases

Andrew L. Snow; Pushpa Pandiyan; Lixin Zheng; Scott M. Krummey; Michael J. Lenardo

Summary:  Controlled expansion and contraction of lymphocytes both during and after an adaptive immune response are imperative to sustain a healthy immune system. Both extrinsic and intrinsic pathways of lymphocyte apoptosis are programmed to eliminate cells at the proper time to ensure immune homeostasis. Genetic disorders of apoptosis described in mice and humans have established Fas and Bim as critical pro‐apoptotic molecules responsible for T‐cell death in response to T‐cell receptor restimulation and cytokine withdrawal, respectively. Emerging evidence prompts revision of this classic paradigm, especially for our understanding of restimulation‐induced cell death (RICD) and its physiological purpose. Recent work indicates that RICD employs both Fas and Bim for T‐cell deletion, dispelling the notion that these molecules are assigned to mutually exclusive apoptotic pathways. Furthermore, new mouse model data combined with our discovery of defective RICD in X‐linked lymphoproliferative disease (XLP) patient T cells suggest that RICD is essential for precluding excess T‐cell accumulation and associated immunopathology during the course of certain infections. Here, we review how these advances offer a refreshing new perspective on the phenomenon of T‐cell apoptosis induced through antigen restimulation, including its relevance to immune homeostasis and potential for therapeutic interventions.


Cytometry Part B-clinical Cytometry | 2009

A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency†

Rebecca A. Marsh; Joyce Villanueva; Kejian Zhang; Andrew L. Snow; Helen C. Su; Lisa Madden; Rajen Mody; Brenda J. Kitchen; Dan Marmer; Michael B. Jordan; Kimberly Risma; Alexandra H. Filipovich; Jack Bleesing

Deficiency of X‐linked inhibitor of apoptosis (XIAP), caused by BIRC4 gene mutations, is the second known cause of X‐linked lymphoproliferative disease (XLP), a rare primary immunodeficiency that often presents with life‐threatening hemophagocytic lymphohistiocytosis (HLH). Rapid diagnosis of the known genetic causes of HLH, including XIAP deficiency, facilitates the initiation of life‐saving treatment and preparation for allogeneic hematopoietic cell transplantation (HCT). Until now, a rapid screening test for XIAP deficiency has not been available.


Biology Direct | 2008

Critical role for BIM in T cell receptor restimulation-induced death

Andrew L. Snow; Joao Bosco Oliveira; Lixin Zheng; Janet K. Dale; Thomas A. Fleisher; Michael J. Lenardo

BackgroundUpon repeated or chronic antigen stimulation, activated T cells undergo a T cell receptor (TCR)-triggered propriocidal cell death important for governing the intensity of immune responses. This is thought to be chiefly mediated by an extrinsic signal through the Fas-FasL pathway. However, we observed that TCR restimulation still potently induced apoptosis when this interaction was blocked, or genetically impaired in T cells derived from autoimmune lymphoproliferative syndrome (ALPS) patients, prompting us to examine Fas-independent, intrinsic signals.ResultsUpon TCR restimulation, we specifically noted a marked increase in the expression of BIM, a pro-apoptotic Bcl-2 family protein known to mediate lymphocyte apoptosis induced by cytokine withdrawal. In fact, T cells from an ALPS type IV patient in which BIM expression is suppressed were more resistant to restimulation-induced death. Strikingly, knockdown of BIM expression rescued normal T cells from TCR-induced death to as great an extent as Fas disruption.ConclusionOur data implicates BIM as a critical mediator of apoptosis induced by restimulation as well as growth cytokine withdrawal. These findings suggest an important role for BIM in eliminating activated T cells even when IL-2 is abundant, working in conjunction with Fas to eliminate chronically stimulated T cells and maintain immune homeostasis.ReviewersThis article was reviewed by Dr. Wendy Davidson (nominated by Dr. David Scott), Dr. Mark Williams (nominated by Dr. Neil Greenspan), and Dr. Laurence C. Eisenlohr.


Nature Genetics | 2017

Germline hypomorphic CARD11 mutations in severe atopic disease

Chi A. Ma; Jeffrey R. Stinson; Yuan Zhang; Jordan K. Abbott; Michael Weinreich; Pia J Hauk; Paul R. Reynolds; Jonathan J. Lyons; Celeste G. Nelson; Elisa Ruffo; Batsukh Dorjbal; Salomé Glauzy; Natsuko Yamakawa; Swadhinya Arjunaraja; Kelsey Voss; Jennifer Stoddard; Julie E. Niemela; Yu Zhang; Sergio D. Rosenzweig; Joshua McElwee; Thomas DiMaggio; Helen F. Matthews; Nina Jones; Kelly D. Stone; Alejandro Palma; Matías Oleastro; Emma Prieto; Andrea Bernasconi; Geronimo Dubra; Silvia Danielian

Few monogenic causes for severe manifestations of common allergic diseases have been identified. Through next-generation sequencing on a cohort of patients with severe atopic dermatitis with and without comorbid infections, we found eight individuals, from four families, with novel heterozygous mutations in CARD11, which encodes a scaffolding protein involved in lymphocyte receptor signaling. Disease improved over time in most patients. Transfection of mutant CARD11 expression constructs into T cell lines demonstrated both loss-of-function and dominant-interfering activity upon antigen receptor–induced activation of nuclear factor-κB and mammalian target of rapamycin complex 1 (mTORC1). Patient T cells had similar defects, as well as low production of the cytokine interferon-γ (IFN-γ). The mTORC1 and IFN-γ production defects were partially rescued by supplementation with glutamine, which requires CARD11 for import into T cells. Our findings indicate that a single hypomorphic mutation in CARD11 can cause potentially correctable cellular defects that lead to atopic dermatitis.

Collaboration


Dive into the Andrew L. Snow's collaboration.

Top Co-Authors

Avatar

Michael J. Lenardo

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Helen C. Su

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kejian Zhang

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Lixin Zheng

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Rebecca A. Marsh

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Alexandra H. Filipovich

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jack Bleesing

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Philip Roehrs

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Scott M. Krummey

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Helen F. Matthews

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge